Last updated: 2026-11-14 13:39:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cingulate Inc. (CING) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.31, with a market capitalization of $65.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.16 to $11.89. This page covers its latest market performance, valuation, price trends and company information.
$65.29M | |
$4.44 | |
$4.53 | |
$4.19 | |
$4.49 | |
174.45K | |
118.31K | |
-- | |
$11.89 | |
$3.16 | |
-- | |
-- |
Cingulate Inc. (CING) last closed at $4.31 as of 2026-11-14 00:31:00, down 4.45% ($0.20) from the previous close of $4.49.
During the latest regular trading session, CING traded between $4.19 and $4.53, with a volume of 174.45K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Cingulate Inc. (CING) moved from $4.24 to $4.31, representing a gain of 1.72% ($0.07).
The stock traded between $4.18 and $4.85 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 129.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 13.2%
CING is currently trading at $4.31, placing it 13.2% of the way from its 52-week low of $3.16 to its 52-week high of $11.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Cingulate Inc. and CING stock.
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.49) by 8.16 percent. This is a 60.74 percent increase over losses of $(1.35) per share from the
Cingulate Inc. reported Q3 2026 financial results with cash of $23.2 million and announced substantial completion of manufacturing work to address FDA CMC information requests for its lead ADHD drug CTx-1301. The company expects to resubmit the NDA between December 2026 and January 2027. The FDA's Complete Response Letter did not raise safety or efficacy concerns. Net loss for nine months ended September 30, 2026 was $22.9 million, with increased SG&A expenses driven by commercial readiness build-out.
Eligible investors can buy real shares of Cingulate Inc. (CING) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CING, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CING shares and USD.
CING Shares to USD
1.00 CING shares = 4.313 USD
Calculations are estimates based on the latest available price and are for reference only.
